Clinical trial NCT05018676: ARX788 in Breast Cancer With Low Expression of HER2
Official title: A Single-arm, Single-center Phase II Clinical Study of Recombinant Humanized Anti-HER2 Monoclonal Antibody-AS269 Conjugate (ARX788) in the Treatment of Unresectable and/or Metastatic Breast Cancer With Low Expression of HER2
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Breast Cancer With Low Expression of HER2
Keywords: ARX788
Breast cancer
Low expression of HER2
Lead sponsor: Fudan University
Sponsor class: OTHER
First posted: 2021-08-24
Enrollment: 54
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A Phase 2 Study of ARX788 in unresectable and/or metastatic breast cancer with low expression of HER2.

Detailed description: A single arm, phase 2 study of ARX788 in unresectable and/or metastatic breast cancer with low expression of HER2. Subjects should received ≥2 lines of systemic chemotherapy regimens for recurrent or metastatic disease, and for HR positive subjects, also need to have received ≥2-line endocrine therapy ± targeted therapy (including neoadjuvant/adjuvant therapy). HER2 low expression is defined as HER2 IHC 1+ or HER2 IHC 2+ and FISH negative. The ARX788 will be administered every 3 weeks (Q3W) intravenous (IV) infusion.

Eligibility criteria: Inclusion Criteria:

* Willing and able to understand and sign an informed consent inform;
* Age ≥18 years, and ≤75 years, male or female;
* Diagnosed as HR arbitrary/HER2 low expression unresectable and/or metastatic breast cancer. HER2 low expression is defined as HER2 IHC 1+ (FISH negative or FISH not done) or HER2 IHC 2+ and FISH negative;
* Received ≥2 lines of systemic chemotherapy regimens for recurrent or metastatic disease, and for HR positive subjects, also need to have received ≥2-line endocrine therapy ± targeted therapy (including neoadjuvant/adjuvant therapy);
* Never had a HER2 positive result (IHC 3+ or FISH+) in previous pathological examinations;
* Have archived or fresh tumor tissue samples for HER2 status confirmation;
* According to the RECIST 1.1 standard, there is at least one measurable lesion;
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or1; LVEF≥50%;
* Adequate organ functions;
* Acute toxicities from any prior therapy, surgery, or radiotherapy must have resolved to Grade ≤1;
* Life expectancy ≥ 3 months.

Exclusion Criteria:

* History of allergic reactions to any component of ARX788, or with a history of protein drug allergy, a history of specific allergies (asthma, rheumatism, eczematous dermatitis), or a history of other severe allergic reactions, who are unsuitable for ARX788 treatment as per the investigator's judgments;
* Previous treatment with T-DM1 or other HER2-ADC drugs;
* Have other malignant tumors within 5 years before signing the informed consent form (except for non-melanoma skin cancer, cervical carcinoma in situ or other tumors that have been effectively treated, except malignant tumors that are considered cured);
* Have primary central nervous system (CNS) tumors or CNS metastases;
* Prior history of interstitial pulmonary disease requiring hormone therapy, drug-induced interstitial pulmonary disease, radiation pneumonia, or current clinically active interstitial pulmonary disease;
* Suffering from keratitis, corneal diseases, retinal diseases or active eye infections that require intervention;
* Unwilling or unable to stop wearing contact lenses for the duration of the study;
* Cardiac insufficiency;
* Uncontrolled hypertension;
* Suffering severe or uncontrolled systemic diseases;
* Had chemotherapy, radiotherapy, or immunotherapy within 4 weeks before the first dose;
* Had breast cancer endocrine therapy within 2 weeks before the first dose;
* Had palliative radiotherapy for bone metastasis within 2 weeks before the first dose;
* Any uncontrolled infection, or other conditions that may limit trial compliance or interfere with evaluation;
* Current known active infection with human immunodeficiency virus (HIV), hepatitis B virus, hepatitis C virus or syphilis;
* Plan to receive major surgical treatment within 2 weeks before first dose or during the trial period, or have suffered severe traumatic injury;
* Pregnancy or lactation;
* Unwilling or unable to use acceptable methods for contraception during the entire treatment period of this trial and within 8 months after the last dose;
* Participated in other clinical trials and used other experimental drugs within 4 weeks before the first dose;
* Any mental or cognitive impairment may limit their understanding and implementation of the informed consent form;
* Not suitable for participating in this trial, such as poor compliance.

Primary outcomes:
measure: Objective remission rate (ORR)
timeFrame: 2 years
Secondary outcomes:
measure: Progression-free survival (PFS)
timeFrame: 2 years
measure: Overall survival (OS)
timeFrame: 2 years
measure: Disease control rate (DCR)
timeFrame: 2 years
measure: Duration of relief (DOR)
timeFrame: 2 years
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Fudan University Shanghai Cancer Center
Study officials:
References: